Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wired Biopharm (operated by Wired Global Holding) is a clinical-stage biotechnology company focused on developing next-generation multi-specific antibodies and antibody-drug conjugates (ADCs) for oncology and immunology. Founded in 2021 by industry veteran Dr. Wei-Dong Jiang, the company leverages its proprietary platform technology to engineer biologics with enhanced therapeutic indices and improved safety profiles. Its lead program, WBD-101, is a bispecific antibody targeting GPC3 and CD3 currently undergoing Phase 1 clinical evaluation for hepatocellular carcinoma. The company maintains dual operations in Shanghai and California to bridge global innovation and manufacturing. Wired Biopharm is backed by top-tier investors including Lilly Asia Ventures and IDG Capital to advance its diverse pipeline of precision medicines.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Wired Biopharm.